medigraphic.com
ISSN 2078-7170 (Electronic)

2013, Number 4

<< Back Next >>

CorSalud 2013; 5 (4)

A historical outline of quinidine

Dorantes SM

Language: Spanish
References: 24
Page: 361-365
PDF size: 394.69 Kb.


Text Extraction

Quinidine, one of the first developed antiarrhythmic drugs, had a significant role in the treatment of various cardiac arrhythmias. Subsequently, concerns arose due to the increased risk of ventricular arrhythmias and increased mortality, so that its use was drastically reduced. However, recent trials have generated a renewed interest in its use: it has been used successfully in idiopathic ventricular fibrillation (IVF), by unknown mechanisms; in Brugada syndrome (BrS), by its action on potassium currents (including Ito), and in short QT syndrome (SQTS), as it normalizes the ventricular refractory period. Therefore, although it is one of the oldest drugs, it has an important role in modern cardiology.


REFERENCES

  1. Belhassen B. Is quinidine the ideal drug for Bruga-da syndrome? Heart Rhythm. 2012;9(12):2001-2.

  2. Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009;122(4):317-21.

  3. Viskin S. Idiopathic ventricular fibrillation "Le syn-drome d'Haissaguerre" and the fear of J waves. J Am Coll Cardiol. 2009;53(7):620-2.

  4. Selzer A, Wray HW. Quinidine syncope, paroxys-mal ventricular fibrillation ocurring during treat-ment of chronic atrial arrhythmias. Circulation. 1964;30(1):17-26.

  5. Márquez MF, Bonny A, Hernández-Castillo E, De Sisti A, Gómez-Flores J, Nava S, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implant-able cardioverter-defibrillator: a case series and literature review. Heart Rhythm. 2012;9(12):1995-2000.

  6. RuDusky BM. Quinidine as an antiarrhythmic. Chest. 2001;119(5):1617-8.

  7. Viskin S, Wilde AAM, Guevara-Valdivia ME, Daou-lah A, Krahn AD, Zipes DP, et al. Quinidine, a life-saving medication for Brugada syndrome, is inac-cesible in many countries. J Am Coll Cardiol. 2013; 61(23):2383-7.

  8. Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. En: Kass RS, Clancy CE eds. Basis and treatment of cardiac arrhythmias. New York: Springer-Verlag Berlín Heidelberg, 2006; p. 305-30.

  9. Olsson G. Market withdrawal of quinidine bisulfate (kinidin durules) in 2006. Heart Rhythm. 2010;7(6): 864.

  10. 10.Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Elec-trophysiol. 2009;32(3):294-301.

  11. 11.Viskin S, Antzelevitch C, Márquez MF, Belhassen B. Quinidine: a valuable medication joins the list of "endangered species". Europace. 2007;9(12):1105-6.

  12. 12.Viskin S, Wilde AAM, Tan HL, Antzelevitch C, Shi-mizu W, Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a pros-pective registry. Heart Rhythm. 2009;6(3):401-4.

  13. 13.Viskin S, Belhassen B, Wilde AAM. Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm. 2010;7(6):863.

  14. 14.Estes NAM, Page RL. Response – Irreplaceable an-tiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm. 2010;7(6):863-4.

  15. 15.Vardas PE, Kanoupakis EM. Old drugs never die; they just fade away. Heart Rhythm. 2010;7(6):864.

  16. 16.Adler A, Nordkamp LO, Crotti L, Schwartz P, Cas-telletti S, Veltmann C, et al. Empiric quinidine for asymptomatic Brugada syndrome – Preliminary results of an international registry. Heart Rhythm. 2012;9(11):1918-9.

  17. 17.Laurent G, Saal S, Amarouch MY, Béziau DM, Mars-man RFJ, Faivre L, et al. Multifocal ectopic Purkinje-related premature contractions. A new SCN5A-re-lated cardiac channelopathy. J Am Coll Cardiol. 2012;60(2):144-56.

  18. 18.Yan GX, Antzelevitch C. Cellular basis for the Bru-gada syndrome and other mechanisms of arrhyth-mogenesis associated with ST segment elevation. Circulation. 1999;100(15):1660-6.

  19. 19.Alings M, Dekker L, Sadee A, Wilde A. Quinidine in-duced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Elec-trophysiol. 2001;24 (9 Pt 1):1420-2.

  20. 20.Belhassen B, Viskin S, Fish R, Glick A, Setbon I, El-dar M. Effects of electrophysiologic-guided thera-py with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventri-cular fibrillation with or without the Brugada syn-drome. J Cardiovasc Electrophysiol. 1999;10(10): 1301-12.

  21. 21.Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defi-brillator the only therapeutic option? Pacing Clin Electrophysiol. 2002;25(11):1634-40.

  22. 22.Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004;43(10):1853-60.

  23. 23.Mok NS, Chan NY, Chiu AC. Successful use of qui-nidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004;27(6 Pt 1):821-3.

  24. 24.Antzelevitch C, Brugada P, Brugada J, Brugada R. Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD ther-apy?. En: Belhassen B, Viskin S, eds. The Brugada syndrome: from bench to bedside. Oxford: Black-well Futura, 2004; p. 202-11.




2020     |     www.medigraphic.com